After Hours
$
44.06
Change
+0.03 +0.07%
Volume
Volume 25,560
Feb 8, 2023, 7:59 p.m.
Quotes are delayed by 20 min
Today's close
$ 47.65
$ 44.03
Change
-3.62 -7.60%
Day low
Day high
$43.94
$47.99

52 week low
52 week high
$27.77
$80.00

Market cap
$3.36B
Average volume
827,640
P/E ratio
N/A
Rev. per Employee
$269,654
EPS
-4.54
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on BEAM
-
The Year's Biggest Healthcare Conference Starts Today
- Barron's Online
-
Pfizer to Pull Back on Rare Disease Research
- Barron's Online
-
11 Cheap Tech Stocks to Consider After the Earnings Deluge
- Barron's Online
-
10 Stocks Driving the Biotech Resurgence
- Barron's Online
-
The Bull Market in Biotech Is Still Going Strong
- Barron's Online
-
25 Stocks That Could Rise on a Short Squeeze
- Barron's Online
-
Canoo and 4 More EV Stocks Are at Risk of a 'Short Squeeze.' Beware.
- Barron's Online
-
Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
- Barron's Online
-
Beam Therapeutics started at market perform with $41 stock price target at BMO Capital
- Tomi Kilgore
-
Intellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents.
- Barron's Online
-
Luck Could Be Improving for the Battered Shares of Las Vegas Sands
- Barron's Online
-
Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases
- Barron's Online
-
Scientists Race to Make Really Big Changes to Your Genes
- Barron's Online
-
bluebird bio Has Good News on Its Gene Therapies
- Barron's Online
- Loading more headlines...
Other News on BEAM
-
IDNA: Healthcare Dashboard For November
- Seeking Alpha
-
ARKK Bears Are Losing Momentum
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Prime Medicine: CRISPR 3.0 Company
- Seeking Alpha
-
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 Update
- Seeking Alpha
-
GNOM: ETF Review And Healthcare Dashboard For October
- Seeking Alpha
-
ARKG: Too Hard To Pin Down, Too Volatile For Comfort
- Seeking Alpha
-
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
- Seeking Alpha
-
Intellia falls as analysts react to CRISPR readouts
- Seeking Alpha
-
Beam Therapeutics: Now Is Not The Right Time To Own
- Seeking Alpha
-
ARKK: Refusing To Fall Below May Lows - Buy This Pullback
- Seeking Alpha
- Loading more headlines...
Press Releases on BEAM
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com